α1-antitrypsin, total, serum; phenotype
3 - 6 days
Turnaround time is defined as the usual number of days from the date of pickup of a specimen for testing to when the result is released to the ordering provider. In some cases, additional time should be allowed for additional confirmatory or additional reflex tests. Testing schedules may vary.
Red-top tube or gel-barrier tube
Separate serum from cells.
Overnight fasting is preferred.
Definitive analysis of hereditary α1-antitrypsin deficiency, which is associated with chronic obstructive pulmonary disease (COPD) (panacinar emphysema), hepatic cirrhosis, and hepatoma. Cholestasis with neonatal hepatitis is found in a minority of neonates with α1AT deficiency.
α1-antitrypsin therapy may alter the patient phenotype.
Phenotype: isoelectric focusing (IEF); total: immunologic
Interpretation accompanies report; phenotypes are designated. PiMM phenotype is normal; PiMZ is heterozygous, intermediate deficient; and PiZZ is homozygous, severely deficient. More than 75 alleles are described; biosynthesis of α1AT is controlled at the Pi locus by a pair of genes. There is codominant expression. The phenotype is “Pi” for protease inhibitor. Z and S are mutant proteins. A null-null state occurs as well. In the dysfunctional type, α1AT is found in normal amounts but does not function normally.
Most pathologic is homozygous state ZZ. An M null genotype will have phenotype as MM, but low serum level of α1AT. α1-antitrypsin deficiency may eventuate in or be associated with cholestatic hepatopathy in infants, a chronic hepatitis, familial infantile cirrhosis, or familial emphysema.1,2 The risks of cirrhosis and development of hepatoma are greater in males.
α1-antitrypsin (α1AT) is a glycoprotein synthesized in the liver and is the main component of the alpha1 globulins. α1AT serves to counter the effects of several serine proteases, including elastase and trypsin. When α1AT is deficient, unopposed activity of these enzymes results in emphysema. The age of occurrence of emphysema varies with the type of deficiency, ZZ being most severe, SZ less severe, and SS least severe. It often varies with the personal habits of the individual, especially regarding smoking. Individuals with α1AT deficiency have PAS-positive diastase-negative granules accumulate in the periportal hepatocytes. Eventually, damage occurs to the liver resulting in cirrhosis. It is especially important to detect α1AT deficiency early as a replacement therapy is now available that has received favorable review in a recent NIH study. Although the long-term effects of this therapy are still unknown, it does have great potential to decrease the severity of emphysema.
α1AT is a positive acute phase protein because it rises whenever there is tissue injury, necrosis, inflammation, or infection. Therefore, patients with α1AT deficiency who suffer from bronchitis, pneumonia, or similar respiratory inflammation may have falsely normal levels during acute illness. After the acute phase of illness has passed, repeat determinations often reveal the “true” or “resting” α1AT level, which is indicative of the heterozygous phenotypic deficiency.
Therefore, use of high-resolution electrophoresis that would detect the slower electrophoretic migration of the Z and S variants is preferred over quantification of α1AT by nephelometry or turbidimetry as a preliminary test for this deficiency. Further, a high-resolution electrophoretic system will detect heterozygotes, which could lead to important family studies of potentially deficient first-degree relatives who may benefit from therapy.
Serum α1AT may be increased in patients during normal pregnancy, chronic pulmonary diseases, hereditary angioneurotic edema, gastric diseases, liver diseases, pancreatitis, diabetes, carcinomas, renal diseases, and rheumatic diseases, and it may be decreased in patients with severe protein loss or in improper storage of specimen.
More than 95% of subjects who are severely deficient are homozygous for the Z allele (PiZZ). PiZZ subjects who smoke have a shorter life expectancy than do nonsmoking PiZZ persons. Variation in severity of clinical manifestations is recognized; some subjects with deficiency do not have significant impairment, but development of airway disease is partly a function of age.
α1AT Concentration (mg/dL)
|Order Code||Order Code Name||Order Loinc||Result Code||Result Code Name||UofM||Result LOINC|
|095653||Alpha-1-Antitrypsin Phenotyp||001982||Alpha-1-Antitrypsin, Serum||mg/dL||1825-9|
|095653||Alpha-1-Antitrypsin Phenotyp||019281||Phenotype (PI)||6770-2|
© 2021 Laboratory Corporation of America® Holdings and Lexi-Comp Inc. All Rights Reserved.
The LOINC® codes are copyright © 1994-2021, Regenstrief Institute, Inc. and the Logical Observation Identifiers Names and Codes (LOINC) Committee. Permission is granted in perpetuity, without payment of license fees or royalties, to use, copy, or distribute the LOINC® codes for any commercial or non-commercial purpose, subject to the terms under the license agreement found at https://loinc.org/license/. Additional information regarding LOINC® codes can be found at LOINC.org, including the LOINC Manual, which can be downloaded at LOINC.org/downloads/files/LOINCManual.pdf